Skip to content
Menu

Citigroup Maintains Buy on Candel Therapeutics, Lowers Price Target to $20

Benzinga Newsdesk 3 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lowers the price target from $26 to $20.

Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lowers the price target from $26 to $20.

Read at benzinga.com